Gainesville, FL, January 28, 2016 --(PR.com
)-- RespiTrend, Inc., developing non-invasive, breath-based, Blood Propofol and Blood Glucose Monitoring technologies.
RespiTrend, Inc., announces it has secured exclusive patent and related rights for two technologies which have the potential to make a major impact on healthcare:
· PROPOTREND™, a non-invasive monitor for the most widely used intravenous anesthetic agent, propofol, which measures changes in the free concentration of propofol in the blood by measuring changes in the propofol concentration in exhaled breath. At present, there is no real-time way for medical practitioners to know how much propofol is reaching the brain. PROPOTREND™ measures the same fraction of propofol that crosses the blood-brain barrier by measuring propofol that crosses the alveolar lining to enter the exhaled breath, taking the guess-work out of propofol induced sedation.
· GLUCOTREND™, a non-invasive blood glucose monitor, which measures changes in the concentration of glucose in the exhaled breath and correlates those changes with changes in blood glucose concentration. According to the International Diabetes Foundation (http://www.diabetesatlas.org), “One in two adults with diabetes is undiagnosed” and is therefore unaware that they are at risk. This technology has the potential to significantly alter that situation by making it more convenient and less painful to determine one’s at-risk status.
These patented technologies (GLUCOTREND™ see US Patent No. 7,914,460; PROPOTREND™, see US Patent Nos. 7,104,963; 6,981,947; 8,211,035, and EPO Patent Nos. EO1610681 and EP2055233) are based on inventions devised by teams of researchers at the University of Florida, including Dr. Richard J. Melker, Dr. Donn M. Dennis, and several of their colleagues. The patents were exclusively licensed by the University of Florida Research Foundation, Inc. to Xhale, Inc., and are now exclusively licensed to RespiTrend, Inc.
“We are committed to taking the PROPOTREND™ and GLUCOTREND™ technologies forward for further development, regulatory review and subsequent market introduction,” said Gerard Bencen, Esq., CEO, President and Chairman of the Board of RespiTrend, Inc. “While Xhale initiated development of these technologies, it has focused its work on its line of nasal alar pulse oximetry sensors and a novel medication adherence monitoring technology for the pharmaceutical industry. As Xhale’s long-time former IP counsel, I am grateful for the opportunity to lead this next phase of technology development for these critically important medical devices,” said Mr. Bencen.
RespiTrend, Inc., is seeking sufficient investment to permit advancement through regulatory approval and market introduction of these technologies. “Commercial success in this effort will provide life-changing, paradigm-shifting, non-invasive medical devices to the medical community and general public,” concluded Mr. Bencen.
About RespiTrend, Inc.
RespiTrend, Inc. (“RTI”) is a medical technology company which is raising capital to advance commercialization of two technology platforms, PROPOTREND™ and GLUCOTREND™ for the healthcare industry.
For further information, please visit http://www.respitrend.com or contact Mr. Bencen at email@example.com